Cargando…
Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma
Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a jo...
Autores principales: | Chen, Qi, Zhao, Min, Yin, Chengliang, Feng, Shiyu, Hu, Jian, Zhang, Qiang, Ma, Xiaodong, Xue, Wanguo, Shi, Jinlong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823878/ https://www.ncbi.nlm.nih.gov/pubmed/31708732 http://dx.doi.org/10.3389/fnins.2019.01137 |
Ejemplares similares
-
Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas
por: Fan, Kun, et al.
Publicado: (2017) -
LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis
por: Shigaki, Hironobu, et al.
Publicado: (2012) -
Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
por: Yin, Chengliang, et al.
Publicado: (2020) -
Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas
por: Yin, Anan, et al.
Publicado: (2017) -
PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)